Another Reason To Watch Kite's CAR-T Results At ASH
This article was originally published in The Pink Sheet Daily
Belldegrun assures the patient death in an ongoing Phase I trial was not related to KTE-C19; further details will be presented at American Society of Hematology meeting in December.
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.